Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3
Hanna Cho, Injae Shin, Hojong Yoon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 11934-11957
Closed Access | Times Cited: 23

Showing 23 citing articles:

The Development of FAK Inhibitors: A Five-Year Update
Andrea Spallarossa, Bruno Tasso, Eleonora Russo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6381-6381
Open Access | Times Cited: 35
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 24
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 9
A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout
Kihyoun Park, Injae Shin, Y. Kim, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Targeting Focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders
Xiao Wang, Na Li, Yunhe Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116678-116678
Closed Access | Times Cited: 7
Identification of Thieno[3,2-d]pyrimidine Derivatives as Potent and Selective Janus Kinase 1 Inhibitors
Younghoon Kim, Eunhye Jeon, Ho Sam Ahn, et al.
European Journal of Medicinal Chemistry (2025), pp. 117308-117308
Closed Access
Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of FAK capable of activating the Hippo pathway for the treatment of esophageal squamous cell carcinoma
Xiao Wang, Yin-Ru Li, Ji Wu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117328-117328
Closed Access
Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase
Younghoon Kim, Pooreum Seo, Eunhye Jeon, et al.
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1414-1420.e5
Open Access | Times Cited: 15
Harnessing the cyclization strategy for new drug discovery
Kai Tang, Shu Wang, Wenshuo Gao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4309-4326
Open Access | Times Cited: 22
Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations
Vincenzo Cilibrasi, Virginia Spanò, Roberta Bortolozzi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114292-114292
Closed Access | Times Cited: 21
Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer
Jinlin Zhang, Kang Xu, Fei Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115192-115192
Closed Access | Times Cited: 13
New pyrimidinothiophene derivatives: Synthesis, spectroscopic analysis, X-ray, DFT calculation, biological activity studies and ADMET prediction
Yuyu Ding, Yan Zhang, Longjia Yan, et al.
Journal of Molecular Structure (2023) Vol. 1290, pp. 135952-135952
Closed Access | Times Cited: 8
Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors
Zhiwu Long, Yaqing Zuo, Rongrong Li, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106792-106792
Closed Access | Times Cited: 8
Design, synthesis and biological evaluation of novel 2,4-diaminopyrimidine cinnamyl derivatives as inhibitors of FAK with potent anti-gastric cancer activities
Yang Liu, Lijun Kong, Na Li, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106895-106895
Closed Access | Times Cited: 8
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment
Chenchen Ma, Siyuan Cui, Ruirong Xu
Current Medicinal Chemistry (2024) Vol. 31, Iss. 29, pp. 4657-4686
Closed Access | Times Cited: 2
Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors
Hongjin Zhang, Guohao Lin, Suyun Jia, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107456-107456
Closed Access | Times Cited: 2
FAK inhibitors in cancer, a patent review – an update on progress
Ya‐Xi Ye, Yuyao Cao, Lisheng Xu, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 593-610
Closed Access | Times Cited: 2
Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase
Mingsong Shi, Tao Chen, Siping Wei, et al.
ACS Omega (2022) Vol. 7, Iss. 36, pp. 32442-32456
Open Access | Times Cited: 14
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Xiuqi Wang, Rosa Anna DeFilippis, Tsigereda Weldemichael, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115977-115977
Closed Access | Times Cited: 5
Development of Novel Focal Adhesion Kinase (FAK) Inhibitors for Targeting Cancer: Structural Insights and Therapeutic Potential
Yingnan Li, Yuming Zhang, Jifa Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116913-116913
Closed Access | Times Cited: 1
Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy
Shibo Zhou, Bo Yang, Yufeng Xu, et al.
Journal of Molecular Modeling (2022) Vol. 28, Iss. 9
Closed Access | Times Cited: 8
Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential
Zhi Xu, Li Wang, Hongyan Hu
Archiv der Pharmazie (2024)
Closed Access
Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase
Younghoon Kim, Christina Seo, Eunhye Jeon, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations
Chuan Guo, Qinxuan Li, Jiujia Xiao, et al.
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 18, pp. 8654-8670
Open Access | Times Cited: 2
Page 1

Scroll to top